Last reviewed · How we verify

Depakote ER

University of Minnesota · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Depakote ER is a Small molecule drug developed by University of Minnesota. It is currently FDA-approved. Also known as: Divalproex, ABT-711, Depakote Extended Release, divalproex sodium.

Depakote ER is a small molecule medication used to treat conditions such as bipolar disorder, mania, and substance abuse, and is available in a long-acting formulation. It is primarily used to prevent seizures in individuals with absence, partial, and generalized seizures, and as a mood stabilizer in the treatment of bipolar disorder.

At a glance

Generic nameDepakote ER
Also known asDivalproex, ABT-711, Depakote Extended Release, divalproex sodium
SponsorUniversity of Minnesota
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Depakote ER

What is Depakote ER?

Depakote ER is a Small molecule drug developed by University of Minnesota.

Who makes Depakote ER?

Depakote ER is developed and marketed by University of Minnesota (see full University of Minnesota pipeline at /company/university-of-minnesota).

Is Depakote ER also known as anything else?

Depakote ER is also known as Divalproex, ABT-711, Depakote Extended Release, divalproex sodium.

What development phase is Depakote ER in?

Depakote ER is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing